BRPI0517742A - method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual - Google Patents
method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individualInfo
- Publication number
- BRPI0517742A BRPI0517742A BRPI0517742-1A BRPI0517742A BRPI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A BR PI0517742 A BRPI0517742 A BR PI0517742A
- Authority
- BR
- Brazil
- Prior art keywords
- influenza virus
- individual
- particle
- cell
- nucleic acid
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MéTODO PARA OBTER UMA PARTìCULA DO VìRUS DA INFLUENZA CONDICIONALMENTE DEFEITUOSA, PARTìCULA DE VìRUS DA INFLUENZA, CéLULA, COMPOSIçãO, USO DA MESMA, MéTODO PARA GERAR PROTEçãO IMUNOLóGICA CONTRA INFECçãO DE UM INDIVìDUO COM UM VìRUS DA INFLUENZA, USO DE UMA PARTìCULA, E, MéTODOS PARA SUPRIR UM áCIDO NUCLEICO QUE NãO CODIFICA UM PEPTìDEO DA INFLUENZA, A UMA CéLULA E A UM INDIVìDUO. A invenção refere-se ao campo do vírus da e da vacinação contra a influenza. A invenção fornece uma partícula do vírus da influenza condicionalmente defeituosa, tendo sete diferentes segmentos de ácido nucleico. A invenção também fornece uma partícula do vírus da influenza condicionalmente defeituosa, faltando-lhe um segmento de ácido nucleico do vírus da influenza, selecionado do grupo de segmentos essencialmente codificando a polimerase acídica (PA), a polimerase básica 1 (PB1) e a polimerase básica 2 (PB2). Em particular, a invenção fornece partículas do vírus da influenza defeituosas, tendo sete diferentes segmentos de ácido nucleico do vírus da influenza e faltando-lhes um segmento do ácido nucleico do vírus da influenza, essencialmente codificando a polimerase acídica. Além disso, a invenção provê o uso de uma composição compreendendo uma partícula do vírus da influenza defeituoso de acordo com a invenção, para a produção de uma composição farmacêutica direcionada à geração de proteção imunológica contra infecção de um indivíduo com um vírus da influenza e fornece um método para gerar proteção imunológica contra infecção de um individuo com um vírus da influenza, compreendendo prover um individuo em necessidade com uma composição compreendendo tal partícula de vírus da influenza defeituosa.METHOD FOR OBTAINING A CONDITIONALLY DEFECTIVE INFLUENUS VIRUS PARTICLE, INFLUENCE VIRUS PARTICLE, CELL, COMPOSITION, USE OF THE SAME, METHOD FOR GENERATING IMMUNE INFUSTIC PROTECTION WITH INFLUENOUS INFUSION TO SUPPLY NUCLEIC ACID THAT DOESN'T CODE A PEPTIDE OF INFLUENCE, A CELL AND AN INDIVIDUAL. The invention relates to the field of influenza vaccination and virus. The invention provides a conditionally defective influenza virus particle having seven different nucleic acid segments. The invention also provides a conditionally defective influenza virus particle, lacking an influenza virus nucleic acid segment selected from the group of segments essentially encoding acidic polymerase (PA), basic polymerase 1 (PB1) and polymerase basic 2 (PB2). In particular, the invention provides defective influenza virus particles having seven different influenza virus nucleic acid segments and lacking one influenza virus nucleic acid segment, essentially encoding the acidic polymerase. In addition, the invention provides the use of a composition comprising a defective influenza virus particle according to the invention for the production of a pharmaceutical composition directed to the generation of immunological protection against infection of an individual with an influenza virus and provides A method for generating immunological protection against infection of an individual with an influenza virus, comprising providing an individual in need with a composition comprising such a defective influenza virus particle.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04105696 | 2004-11-11 | ||
EP05105708 | 2005-06-27 | ||
PCT/EP2005/055808 WO2006051069A2 (en) | 2004-11-11 | 2005-11-08 | Defective influenza virus particles |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0517742A true BRPI0517742A (en) | 2008-10-21 |
Family
ID=39869799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517742-1A BRPI0517742A (en) | 2004-11-11 | 2005-11-08 | method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN102586199A (en) |
BR (1) | BRPI0517742A (en) |
TW (1) | TW200621286A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201310031D0 (en) * | 2013-06-05 | 2013-07-17 | Pirbright Inst The | Cell |
EP3063273B8 (en) * | 2013-10-28 | 2020-12-30 | Blue Sky Vaccines GmbH | Influenza virus vector for virotherapy |
WO2023138651A1 (en) * | 2022-01-19 | 2023-07-27 | Versitech Limited | Rationally designed single-round infectious virus and methods of use thereof |
-
2005
- 2005-11-08 TW TW094139113A patent/TW200621286A/en unknown
- 2005-11-08 BR BRPI0517742-1A patent/BRPI0517742A/en not_active IP Right Cessation
- 2005-11-08 CN CN2012100295719A patent/CN102586199A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW200621286A (en) | 2006-07-01 |
CN102586199A (en) | 2012-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006051069A3 (en) | Defective influenza virus particles | |
CO6470863A2 (en) | MUTANTS FGF21 AND USES OF THE SAME | |
CY1123901T1 (en) | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | |
CY1120622T1 (en) | METHODS AND COMPOSITIONS FOR INDICATION OF AN IMMUNE RESPONSE TO EGFRVIII | |
NO20006328D0 (en) | Attenuated negative strand virus with altered interferon antagonist activity for use as vaccines and drugs | |
CO2018003131A2 (en) | Oral care compositions comprising a basic amino acid, a combination of zinc ion sources and a thickener system | |
Lalor et al. | Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus | |
RS52537B (en) | Activin-actrii antagonists and uses for treating anemia | |
BRPI0518568A2 (en) | Method for producing a replicative influenza virus particle without the use of helper virus, replicative influenza virus particle, Cell, composition, use of a composition, Method for generating immunological protection against infection of an individual with an influenza virus, , Nucleic acid | |
EA033386B1 (en) | Recombinant immunogenic influenza a virus hemagglutinin stem domain polypeptides and use thereof | |
BRPI0707543B8 (en) | polypeptide composition and use thereof | |
NO20082149L (en) | Canine flu viruses and related compositions and methods of use | |
Lee et al. | Influenza viruses: innate immunity and mRNA vaccines | |
BR112015025558A2 (en) | mouthwash compositions containing silsesquioxane polyiorgan particles | |
BR0312173A (en) | Recombinant cdna molecule, molecule and sequence, vector, process for preparing infectious measles virus particles, immunogenic composition, vaccine composition, and recombinant mononegaviral virus | |
NO20092254L (en) | Powder formulations for valganciclovir | |
BR112022000490A2 (en) | pharmaceutical composition | |
BRPI0517742A (en) | method for obtaining a conditionally defective influenza virus particle, influenza virus particle, cell, composition, use thereof, method for generating immunological protection against infection of an individual with an influenza virus, use of a particle, and, methods to supply a nucleic acid that does not encode an influenza peptide to a cell and an individual | |
MX2022012251A (en) | Universal influenza vaccine using nucleoside-modifield mrna. | |
MX2020011586A (en) | Synthetic chimeric vaccinia virus. | |
BR112015032556A2 (en) | MODIFIED MATRIX PROTEIN (M) FROM A VESICULAR STOMATITIS VIRUS (VSV); NUCLEOTIDE SEQUENCE ENCODING A MODIFIED MATRIX PROTEIN OF A VESICULAR STOMATITIS VIRUS; RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV); VACCINE; PREPARATION AND BOOST COMBINATION VACCINE; KIT; ISOLATED PEPTIDE; ISOLATED NUCLEOTIDE SEQUENCES; USE OF THE VACCINE; USE OF THE PREPARATION AND BOOST COMBINATION VACCINE; METHOD FOR INDUCING AN IMMUNE RESPONSE IN AN INDIVIDUAL | |
Stephenson et al. | Influenza: current threat from avian influenza | |
MX2022002766A (en) | Influenza virus vaccines and uses thereof. | |
Kocaağaoğlu et al. | An assessment of shear bond strength between ceramic repair systems and different ceramic infrastructures | |
WO2018013704A1 (en) | Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) , Free format text: TRANSFERIDO DE: SOLVAY PHARMACEUTICALS B.V. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) , |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014. |